Translational research in academia and industry

Experimental Biology and Medicine

Volumn 231, Issue 11, 2006, Pages 1685-1689

  Clackson, Tim ^a  

^a ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

Academia; Industry; Interdisciplinary research; Oncology; Translational research

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACADEMIC ACHIEVEMENT; BIOMEDICINE; CHEMISTRY; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFERENCE PAPER; DIMERIZATION; IMMUNOHISTOCHEMISTRY; INDUSTRIAL MEDICINE; MEDICAL RESEARCH;

EID: 33845274056     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/153537020623101104     Document Type: Conference Paper

References (14)

1. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Prac Oncol 2:554-561, 2005.
2. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65:7525-7529, 2005.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 250:2129-2139, 2004.
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004.
5. Lengauer C, Diaz LA, Saha S. Cancer drug discovery through collaboration. Nat Rev Drug Disc 4:375-380, 2005.
6. Clackson T. Controlling protein-protein interactions using chemical inducers and disrupters of dimerization. In: Schreiber SL, Kapoor T, Wess G, Eds. Chemical Biology. Weinheim, Germany: Wiley-VCH, in press.
7. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science 262:1019-1024, 1993.
8. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41:870-879, 2001.
9. Ye X, Rivera VM, Zoltick P, Cerasoli F Jr, Schnell MA, Gao G, Hughes JV, Gilman M, Wilson JM. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283:88-91, 1999.
10. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T, Wilson JM. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105:1424-1430, 2005.
11. Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, Clackson T. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97:1249-1257, 2001.
12. Berger C, Blau CA, Huang ML, Iuliucci JD, Dalgarno DC, Gaschet J, Heimfeld S, Clackson T, Riddell SR. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103:1261-1269, 2004.
13. Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL, von Kalle C, Schmidt M, Peterson LJ, Morris JC, Richard RE, Clackson T, Kiem HP, Blau CA. Pharmacologically regulated in vivo selection in a large animal. Blood 100:2026-2031, 2002.
14. http://www.ariad.com/regulationkits